The estimated Net Worth of Capital Management Lp Camber is at least $90.5 Million dollars as of 7 August 2019. Capital Camber owns over 385,000 units of Protalix BioTherapeutics stock worth over $4,565,600 and over the last 9 years Capital sold PLX stock worth over $85,958,300.
Capital has made over 7 trades of the Protalix BioTherapeutics stock since 2015, according to the Form 4 filled with the SEC. Most recently Capital sold 4,390,000 units of PLX stock worth $59,572,300 on 1 October 2020.
The largest trade Capital's ever made was selling 4,390,000 units of Protalix BioTherapeutics stock on 1 October 2020 worth over $59,572,300. On average, Capital trades about 1,609,428 units every 226 days since 2015. As of 7 August 2019 Capital still owns at least 4,390,000 units of Protalix BioTherapeutics stock.
You can see the complete history of Capital Camber stock trades at the bottom of the page.
Capital's mailing address filed with the SEC is 101 Huntington Ave #2550, Boston, MA 02199, USA.
Over the last 18 years, insiders at Protalix BioTherapeutics have traded over $46,705,936 worth of Protalix BioTherapeutics stock and bought 4,403,619 units worth $4,673,005 . The most active insiders traders include Phillip Md Et Al Frost Gamm..., Capital Management Lp Camber, and Ltd Bio Cell. On average, Protalix BioTherapeutics executives and independent directors trade stock every 88 days with the average trade being worth of $404,231. The most recent stock trade was executed by Dror Bashan on 19 October 2023, trading 64,516 units of PLX stock currently worth $90,322.
protalix is a publicly traded, clinical stage biopharmaceutical company (nyse, tase: plx) focused on the development and commercialization of recombinant therapeutic proteins using its proprietary procellex™ plant cell culture protein expression system. procellex provides a unique platform on which we have established a pipeline of proprietary and biosimilar versions of recombinant therapeutic proteins, relying upon known biological mechanisms of action. protalix's lead product, taliglucerase-alfa is an enzyme replacement therapy for the treatment of gaucher´s disease. protalix has concluded phase iii studies for this drug and is currently undergoing fda review. treatment is currently being provided by protalix to gaucher patients under clinical studies and companionate programs to hundreds of patients worldwide. this product has been licensed to pfizer. protalix's pipeline includes multiple therapeutic protein candidates including: acetylcholinesterase (biodefense); alfa‐galactosidase
Protalix BioTherapeutics executives and other stock owners filed with the SEC include: